In order for Dr Hahn’s vision to become a reality we need better real world data but not at the expense of the common rule and patient consent. Balance is needed to ensure patient protection and allow the advancements of science.
Okay - have you ever seen this on PET scan? Metastatic appearing bright lesions like one to the left in many places - but this acetabellum looks periosteal only - still looking for malignancy source biopsy x 2 negative
Great article from Vivek Subbiah MD (@VivekSubbiah) at MD Anderson outlining a blueprint of where "The next generation of evidence-based medicine" will come from. Grateful for his highlighting our pre-competitive effort as part of this future.
https://t.co/WBMALavR9k
@FilipJankuMD@ASCO I received my 20 year ribbon as well and felt the exact same. But, somehow it feels strangely appropriate after the 2 year hiatus of ASCO meetings. It’s good to be together again in person!
To demonstrate our commitment to improving healthcare outcomes for everyone, Taproot has become a public benefit corporation (PBC). A PBC is a unique type of corporation that balances the pursuit of a public good with fiduciary responsibility.
#data#research#cure
@Dr_R_Kurzrock Even NCCN leadership has said that following guidelines 80- 85% is probably appropriate, recognizing that data is rapidly evolving and the guidelines may not appropriately advance or retire recommendations in a timely fashion.
@davidcnorrismd @VivekSubbiah@NEJM@manjuggm@weoncologists@FDAOncology I can’t help but think of capecitabine (Xeloda) as another example pf chemotherapy drug that most oncologist find equal benefit using lower dose with less SAE.
Every component and every combination of components can lead to false discovery (false positives or false negatives). Individual components of cancer mutation calling should never be considered 'plug and play'."
Thank you FDA-CDRH for this work! Thank you Wenming Xioa et. al.
Molecular testing at the center of unlocking personalized cancer care is extremely complex. This is in the testing alone. What about the clinical outcome tied to molecular testing ? Can we ever unlock personalized oncology with tying testing to outcomes?
https://t.co/MRjGT4C061
"Detection of cancer mutations is an integrated process. No individual component can be singled out in isolation as more important than any other, and specific components affect and interact with each other.
Way to go ABIM! “Spreading misinformation or falsehoods during a time of a public health emergency goes against everything our board certified physicians stand for. The evidence that we have safe, effective and widely available vaccines against COVID-19 is overwhelming.”
Taproot Health is excited to welcome Renee Ubico as Clinical Site Manager. Renee has over a decade of experience in building relationships between medical providers, patients, and research teams. Click here to learn more: https://t.co/oc5D2mLXCO #leadership#data#research
Exciting news in #cancerresearcher A new light activated cancer drug could kill cancer without harming healthy tissues. This drug acts like a Trojan Horse, disguising itself as food and tricking malignant cells to consume it. #endcancer#oncology https://t.co/NPPgWgXUFn
@JAMAOnc today
"To fulfill the promise of precision medicine in oncology, we . . . need to further understand if drugs with specific targets have activity in specific groups of patients rather than “all-comers.”
https://t.co/hQhT4JNrNq
@marklewismd Mark - well said. The complexities we all face as oncologist is so poorly understood by so many outside observers. Covid may be the straw (or beam) that breaks many backs